Table 3.

Changes in BW and WC according to the AMY1-AMY2 rs11185098 genotype

	Model 1		Model 2		Model 3		Model 4
Outcome	β (SE)	P value	β (SE)	P value	β (SE)	P value	β (SE)	P value
6 months
Δ BW	−0.78 (0.35)	0.027	−0.70 (0.35)	0.044	−0.64 (0.35)	0.067	−0.67 (0.35)	0.056
Δ WC	−1.21 (0.38)	0.002	−1.06 (0.37)	0.005	−1.01 (0.37)	0.007	−1.02 (0.37)	0.006
12 months
Δ BW	−1.30 (0.47)	0.005	−1.21 (0.46)	0.009	−1.09 (0.46)	0.018	−1.15 (0.46)	0.014
Δ WC	−1.55 (0.49)	0.002	−1.38 (0.48)	0.004	−1.31 (0.48)	0.007	−1.35 (0.48)	0.005
18 months
Δ BW	−1.70 (0.52)	0.001	−1.63 (0.52)	0.002	−1.55 (0.52)	0.003	−1.59 (0.52)	0.003
Δ WC	−1.51 (0.54)	0.005	−1.39 (0.53)	0.009	−1.31 (0.53)	0.014	−1.39 (0.53)	0.009
24 months
Δ BW	−1.34 (0.49)	0.006	−1.27 (0.49)	0.01	−1.19 (0.49)	0.015	−1.23 (0.49)	0.012
Δ WC	−1.57 (0.52)	0.003	−1.43 (0.51)	0.005	−1.39 (0.51)	0.006	−1.41 (0.51)	0.006

β represents changes in outcomes by increasing number of A alleles. Model 1: age, sex, ethnicity, and diet group. Model 2: age, sex, ethnicity, diet group, and value for the respective outcome traits at the baseline examination (either BW or WC). Model 3: age, sex, ethnicity, diet group, BMI at baseline, WC at baseline, and glucose at baseline. Model 4: model 3 + antihypertensive medication use at baseline and lipid-lowering medication use at baseline.